The gene replacement therapy onasemnogene abeparvovec became available in 2019, and risdiplam, an SMN2 pre-mRNA splicing modifier, was introduced for the early treatment of SMA in 2021. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.